Related Experiment Video
Updated: Feb 27, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
Jonathan M Lehman1, Mary E Gwin2, Pierre P Massion3,4,5
1Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA.
Abstract:
Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and "smart bomb"-based drug/radioconjugates have led to good response in early clinical trials. Additionally, new research insights into the genetics and tumor heterogeneity of SCLC alongside the availability of new tools such as patient-derived or circulating tumor cell xenografts offer the potential to shine light on this beshadowed cancer.
Insights
Small cell lung cancer (SCLC) remains aggressive with limited treatment advances. Emerging immunotherapies, targeted drugs, and novel research tools offer new hope for this challenging neuroendocrine cancer.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, responsible for approximately 15% of lung cancer deaths.
- Standard treatment options for SCLC have seen minimal improvement over the past three decades.
- SCLC's high mortality rate underscores the urgent need for innovative therapeutic strategies.
Purpose of the Study:
- To review recent advancements and emerging therapies for small cell lung cancer.
- To highlight new research insights into SCLC genetics and tumor heterogeneity.
- To discuss the potential of novel tools in advancing SCLC research and treatment.
Main Methods:
- Review of current clinical practices and emerging therapeutic modalities.
- Analysis of recent research findings on SCLC genetics and tumor biology.
- Evaluation of novel preclinical and clinical research tools, including xenografts.
Main Results:
- Immunotherapies and checkpoint inhibitors are being integrated into clinical practice for SCLC.
- Targeted therapies are demonstrating promising results in early clinical trials.
- Drug/radioconjugates, described as "smart bombs," have shown favorable responses in initial studies.
- New genetic and heterogeneity insights are emerging for SCLC.
- Advanced tools like patient-derived and circulating tumor cell xenografts are becoming available.
Conclusions:
- Emerging immunotherapies, targeted agents, and drug/radioconjugates represent significant progress in SCLC treatment.
- Enhanced understanding of SCLC genetics and heterogeneity, coupled with new research tools, offers a promising future for this disease.
- These advancements provide renewed hope for improved outcomes in patients with small cell lung cancer.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...